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Objectives: Helicobacter pylori eradication remains a challenge. Non-bismuth-based quadruple regimens (NBQR)
have shown high eradication rates (ER) elsewhere that need to be locally confirmed. The objective of this study
was to compare the first-line ER of a hybrid therapy (20 mg of omeprazole twice daily and 1 g of amoxicillin twice
daily for 10 days, adding 500 mg of clarithromycin twice daily and 500 mg of metronidazole every 8 h for the last
5 days; OA-OACM) with that of a 10 day concomitant regimen consisting of taking all four drugs twice daily every
day (including 500 mg of metronidazole every 12 h; OACM). A 10 day arm with standard triple therapy (OAC;
20 mg of omeprazole/12 h, 1 g of amoxicillin/12 h and 500 mg of clarithromycin/12 h) was included.
Patients and methods: Three hundred consecutive patients were randomized (1:2:2) into one of the three
following regimens: (i) OAC (60); (ii) OA-OACM (120); and (iii) OACM (120). Eradication was generally confirmed
by a [13C]urea breath test at least 4 weeks after the end of treatment. Adverse events and compliance were
assessed. EudraCT: 2011-006258-99.
Results: ITT cure rates were: OAC, 70.0% (42/60) (95% CI: 58.3–81.7); OA-OACM, 90.8% (109/120) (95% CI:
85.6–96.0); and OACM, 90.0% (107/119) (95% CI: 84.6–95.4). PP rates were: OAC, 72.4% (42/58) (95% CI:
60.8–84.1); OA-OACM, 93.9% (108/115) (95% CI: 89.5–98.3); and OACM, 90.3% (102/113) (95% CI: 84.8–
95.8). Both NBQR significantly improved ER compared with OAC (P,0.01), but no differences were seen between
them. Mean compliance was elevated [98.0% (SD¼9.8)] with no differences between groups. There were more
adverse events in the quadruple arms (OACM, 65.8%; OA-OACM, 68.6%; OAC, 46.6%; P,0.05), but no significant
differences between groups in terms of severity were seen.
Conclusions: Hybrid and concomitant regimens show good ER against H. pylori infection with an acceptable
safety profile. They clearly displace OAC as first-line regimen in our area.
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Helicobacter pylori eradication remains a challenge, mainly due to
a loss of efficacy of classic clarithromycin-based triple therapy
regimens, which in turn is related to an increase in clarithromycin
resistance.1,2 In order to overcome this shortcoming, new
regimens have been proposed. In particular, much attention has
been focused on two non-bismuth-based quadruple regimens
(NBQR): sequential and concomitant. Sequential treatment
consists of a 10 day treatment in which proton pump inhibitor
(PPI) plus amoxicillin is given for 5 days followed by a PPI plus cla-
rithromycin and a nitroimidazole for 5 days. The concomitant
treatment is a quadruple regimen containing a PPI, amoxicillin,
clarithromycin and a nitroimidazole for a variable period between
5 and 14 days. Both NBQR have shown a significant advantage
over the standard triple therapy (omeprazole/amoxicillin/
clarithromycin).3 – 5 A recent meta-analysis comparing these
NBQR has revealed a significant advantage of concomitant ther-
apy.6 The high eradication rates (ER) (≥90%) that have been
reported for NBQR support the most recent recommendations in
European countries to incorporate them as first-line empirical
treatments.2,7
A hybrid NBQR that consists of continuing amoxicillin into the
second part of the sequential treatment has recently displayed
good results.1,8 – 10 Such results, however, have to be confirmed
locally in an area like ours with low–intermediate resistance to cla-
rithromycin (≤15%), as previously reported.11,12 Furthermore, there
is a need to explore whether shortening hybrid regimens maintains
efficacy in addition to ameliorating safety and compliance.
Our objective was to compare the efficacy and safety of two
10 day NBQR (i.e. hybrid and concomitant) and assess both
against omeprazole/amoxicillin/clarithromycin.
Patients and methods
Patients, treatments and follow-up
This was a multicentre, open-label, controlled, three arm, parallel-group,
Phase IV non-commercial trial with imbalanced randomization (1:2:2)
designed to examine the superiority of two NBQR against H. pylori over
omeprazole/amoxicillin/clarithromycin. It was conducted at three centres
in northern Spain from July 2012 to December 2013. Eligible participants
were all H. pylori-positive adult consecutive patients aged 18–75 years
who were referred to each centre, and met the eligibility criteria for eradi-
cation therapy according to the current recommendations.7 H. pylori infec-
tion was confirmed by at least one of the following methods: [13C]urea
breath test, histology or rapid urease test. Written informed consent
was obtained from all patients before enrolment. Previous H. pylori eradi-
cation therapy was an exclusion criterion for the study. Other exclusion
criteria were: age ,18 years or .75 years, serious concomitant illnesses,
gastric surgery, allergy to any of the study drugs, intake of antibiotics
or bismuth salts within the last month or PPIs within the last 2 weeks,
and pregnancy or breastfeeding. The study was approved by the regional
Ethics Committee and was registered in the European Union Clinical Trials
Register Database (Clinicaltrialsregister.eu; EudraCT: 2011-006258-99).
A randomization sequence was created using Stata 12/SE (StataCorp,
College Station, TX, USA) statistical software using random block sizes of
10 and imbalanced according to the schedule 1:2:2 to allocate patients
respectively to groups: (i) OAC—20 mg of omeprazole/12 h, 1 g of amoxi-
cillin/12 h and 500 mg of clarithromycin/12 h; (ii) OA-OACM (hybrid ther-
apy)—20 mg of omeprazole/12 h and 1 g of amoxicillin/12 h for 10 days
adding 500 mg of clarithromycin/12 h and 500 mg of metronidazole/8 h
only for the last 5 days; and (iii) OACM (concomitant therapy)—20 mg of
omeprazole/12 h, 1 g of amoxicillin/12 h, 500 mg of clarithromycin/12 h
and 500 mg of metronidazole/12 h. All drugs were taken orally on a
10 day-based regimen. Allocation concealment was guaranteed. All
drugs used were of generic branding and purchased from Normon
Pharmaceutical Laboratories (Madrid, Spain). An investigator who did
not have clinical involvement in the trial was in charge of allocating
patients according to a computer-generated numerical sequence on a
phone request for all centres. The coordinators and the investigators in
the centres did not know the details of the allocation sequence. This
study was regarded as an open trial keeping in mind the number of
drugs to be taken, the different dosage schedules and the fact that the
principal outcome (H. pylori ER) was not influenced by the unblinded
design of the protocol. Personnel carrying out urea breath tests were
blind to the treatment given. The study drugs were handed to the patient
in a registered box prepared by a pharmacist that included all required pills
and a day-by-day intake scheme. Compliance was assessed by personal
interview and standard pill count after ending treatment. Patients who
used ,80% of the study medication were considered non-compliant.
The primary endpoint (H. pylori ER by ITT) was defined as a negative
[13C]urea breath test performed at least 4 weeks after completion of treat-
ment, as recommended by the manufacturer (Otsuka Pharmaceutical
Europe Ltd). If a patient required a follow-up endoscopy, eradication
was considered achieved when two direct methods (i.e. histology and
urease test) were negative 4 weeks after the end of treatment; this excep-
tion was only applied to four patients (one in the OAC arm and three in the
OACM arm). Neither antibiotics nor PPI were allowed during the 4 or 2 week
period, respectively, prior to H. pylori reassessment. As a secondary end-
point, safety was evaluated by means of recording adverse events through
open-answer questions. All adverse events were evaluated by their doc-
tors and classified according to their intensity and causality. Relevant
method changes after trial commencement were not performed.
Statistical analysis
H. pylori ER were calculated by ITT and PP analyses. For ITT analysis, all
randomized patients enrolled into the study were included; patients with-
out an observed outcome were considered as treatment failures. For PP
analysis, all protocol violators (i.e. non-compliant patients and patients
lost to follow-up) were excluded. Categorical variables are described
with percentages, and continuous variables are described with mean
and standard deviation or median and range as appropriate. For univariate
statistical analysis, a 95% CI, Student’s t-test and Fisher’s exact test were
applied. Multivariate logistic regression analyses were also performed to
evaluate independent predictive variables for eradication of H. pylori. The
magnitude of the effect was described with OR and 95% CI. The variables
chosen to be introduced in predictive models depended on the statistical
significance in univariate analysis or at least those known to have potential
events based on the literature. P values ,0.05 were considered statistically
significant after Bonferroni adjustment when necessary. No interim ana-
lyses for efficacy or futility were conducted.
In order to estimate the sample size, we assumed the following
parameters based on several previous studies:9,13 – 15 80% ER in the control
arm, 15% improvement in the intervention arms, a error before Bonferroni
correction¼5%, and b error¼20%. With a 1:2 ratio (control:intervention
arms), the estimated sample size was 60 patients in the control arm and
120 patients in the intervention arms. The statistical software package
Stata 12/SE was used for the analyses.
Results
All eligible patients who accepted participation were recruited.
Figure 1 shows the patient flow chart, according to the
CONSORT statement advice. The baseline demographic and
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Figure 1. Flow diagram of the subjects enrolled in the study. AE, adverse events. *Diagnosis of H. pylori infection was based on serology in patient no. 48.
**Patients without an observed outcome were considered as treatment failures.
Table 1. Demographic and clinical characteristics of patients for the total cohort and therapeutic subgroups after randomization
Total cohort OAC OA-OACM OACM P
Number of patients 300 60 120 120
Male/female, n/n 115/185 25/35 49/71 41/79 0.45
Age (years), median (range) 44 (18–69) 45 (20–65) 41 (18–66) 47 (24–69) 0.07
Smoking habit (number of cigarettes/day), mean (SD) 3.8 (7.4) 3.0 (6.5) 4.0 (7.1) 4.0 (8.1) 0.68
Alcohol intake (g/day), mean (SD) 3.8 (15.0) 2.9 (9.5) 2.0 (9.4) 6.0 (20.5) 0.11
Co-medication, n (%) 139 (46.3) 24 (40.0) 53 (44.2) 62 (51.6) 0.42
Indication, n (%) 0.67
functional dyspepsia 221 (73.7) 46 (76.7) 93 (77.5) 82 (68.3)
gastric/duodenal ulcer 50 (16.7) 10 (16.7) 16 (13.3) 24 (20.0)
familial gastric cancera 25 (8.3) 4 (6.7) 9 (7.5) 12 (10.0)
intestinal metaplasia/gastric atrophy 4 (1.3) 0 (0.0) 2 (1.7) 2 (1.7)
Diagnostic method, n (%) 0.57
rapid urease test 172 (57.3) 38 (63.3) 72 (60.0) 62 (51.7)
histology 104 (34.7) 19 (31.7) 40 (33.3) 45 (37.5)
urea breath test 15 (5.0) 2 (3.3) 5 (4.2) 8 (6.7)
combinedb 7 (2.3) 0 (0.0) 3 (2.5) 4 (3.3)
aGastric cancer in first-degree relatives.













clinical characteristics of the total cohort and each therapeutic
group are listed in Table 1. The three groups were similar in
terms of age, gender, smoking habit, use of co-medication and
indication for H. pylori eradication. Functional dyspepsia was the
most common indication for H. pylori eradication (73.7%). There
was only one protocol deviation that referred to a patient included
in the OACM group who did not fulfil the inclusion criteria—he was
included on the basis of positive H. pylori serology. This case was
also excluded from the ITT analysis. Overall, four patients (two in
the OAC group and two in the OA-OACM group) were lost to
follow-up. Finally, six patients in the OACM group and two patients
in the OA-OACM group discontinued the assigned treatment due
to adverse events. Another patient in the OA-OACM group had low
compliance and was also excluded from the PP analysis. In sum-
mary, 299 patients were included in the ITT analysis and 286 in
the PP analysis (see Figure 1).
Tables 2 and 3 summarize the outcomes of the three arms in
terms of ER and Tables 4 and 5 show data on compliance and
adverse events during the study. NBQR showed significantly better
ER against H. pylori than the OAC in both ITT and PP analysis
(Tables 2 and 3). No statistical differences were found between
the two alternative regimens. After adjusting for age, sex,
co-medication, number of cigarettes, alcohol consumption in
grams and indication, in the multivariate analysis, the results
were unaltered (Table 3).
Compliance with the assigned treatment was high with no sig-
nificant statistical differences between the three arms (Table 4),
although more patients in the quadruple arms discontinued the
intervention because of adverse events or poor tolerance to the
respective treatments (not significant) (Figure 1). Additionally,
there was a higher rate of adverse events in the quadruple arms
of the study that reached statistical significance in terms of fre-
quency (Table 5). In particular, diarrhoea and headache were
more frequent in quadruple regimens compared with the OAC
(Table 5). However, there were no differences between the three
arms in terms of the severity of the adverse events and no serious
side effects were reported throughout the study.
Discussion
The present study demonstrates similar high ER (90%) of two
NBQR (hybrid and concomitant) against H. pylori in our area,
Table 2. Outcomes of the three arms of the study in terms of efficacy (ER);
univariate analysis
Group n % (95% CI) OR (95% CI) P
ITT analysis
OAC 42/60 70.0 (58.3–81.7) 1 —
OA-OACM 109/120 90.8 (85.6–96.0) 4.3 (1.8–10.1) 0.002
OACM 107/119 90.0 (84.6–95.4) 3.82 (1.7–8.9) 0.004
PP analysis
OAC 42/58 72.4 (60.8–84.1) 1 —
OA-OACM 108/115 93.9 (89.5–98.3) 5.9 (2.1–16.1) 0.001
OACM 102/113 90.3 (84.8–95.8) 3.5 (1.5–8.5) 0.01




OR (95% CI) P OR (95% CI) P
OAC 1 — 1 —
OA-OACM 4.8 (1.9–11.6) 0.002 6.2 (2.3–16.6) ,0.001
OACM 4.9 (2.0–12.0) 0.002 4.8 (1.9–12.0) 0.002
aMultivariate analysis after adjusting for age, sex, associated drugs,
number of cigarettes, clinical indication and alcohol intake in grams
(P values after Bonferroni adjustment).





Total cohort 98.0 (9.8)
Table 5. Adverse events in the study population
Total cohort (n¼300) OAC (n¼60) OA-OACM (n¼120) OACM (n¼120) P
Adverse eventsa 187 (62.3) 27 (45.0) 81 (67.5) 79 (65.8) 0.012
metallic taste 66 (22.0) 11 (18.3) 25 (20.8) 30 (25.0) 0.55
diarrhoea 95 (31.7) 7 (11.7) 40 (33.3) 48 (40.0) 0.001
nausea, dyspepsia 93 (31.0) 13 (21.7) 44 (36.7) 36 (30.0) 0.12
headache 56 (18.7) 4 (6.7) 26 (21.7) 26 (21.7) 0.03
mucosal complaintsb 22 (7.3) 3 (5.0) 8 (6.7) 11 (9.2) 0.56
anxiety 8 (2.7) 2 (3.3) 4 (3.3) 2 (1.7) 0.68
dizziness 3 (1.0) 1 (1.7) 1 (0.8) 1 (0.8) 0.84
others 38 (12.7) 3 (5.0) 15 (12.5) 20 (16.7) 0.08
Data are shown as n (%).
aNumber of adverse events relative to all patients included in each cohort (total, OAC, OA-OACM and OACM cohorts).
bIncludes aphthous stomatitis, vulvar pruritus and probable local fungal infection.













clearly exceeding that achieved by the OAC (70%). Although the
NBQR were associated with a greater number of adverse events,
we did not find differences in either severity of adverse events or
compliance between the arms.
A 10 day concomitant NBQR is currently recommended as a
first-line choice in Spain, a suggestion that is supported by solid
evidence indicating ER 90%.3,4,7 Our study, which shows similar
ER with two NBQR, is also comparable to another recent Spanish
clinical trial.16 Sequential NBQR, although initially promising,17,18
has recently revealed poor results and is no longer considered a
good option for overcoming antibiotic resistance.19 – 23
A hybrid NBQR consisting of dual therapy with a PPI and
amoxicillin for 14 days with clarithromycin and metronidazole
added for the last 7 days (all of them twice daily) has shown
97.4% ER on ITT.9 A 90% ER has recently been reported in Spain
and Italy with a similar regimen in a study where high rates
of antibiotic resistance were seen, while others reached just 80%
ER in Italy.8,24 A shorter duration of this new regimen (10–12 days)
has recently been achieved, showing high ER (93%–95%).13 We
have obtained results comparable to a 10 day hybrid regimen in an
area with higher rates of resistance to clarithromycin, which are also
in accordance with the aforementioned Spanish study.8,11,13 This
evidence shows that optimized hybrid and concomitant therapies
can eradicate H. pylori in .90% of patients in areas of growing
antibiotic resistance.25
The rate of adverse events obtained with our NBQR was slightly
higher than, but similar to, results previously reported and was
significantly higher than that achieved with OAC.8 Considering
the mild degree of such adverse events, the benefits outweighed
the risks. A recent meta-analysis has concluded that there were
no significant differences between the three NBQR in terms of
adverse events or compliance.26
One limitation of our study is that it was carried out in a single
region and the results will need to be confirmed in regions with
different patterns of resistance. Moreover, we did not perform a
concurrent in vitro susceptibility study to check for H. pylori resist-
ance. Nevertheless, a recent report from our group and the last
European survey on antibiotic resistance of H. pylori showed that
our region was still a low-resistance area (14%) at the time this
study was designed and initiated.11,12Finally, we changed the dosage
schedule of metronidazole in our hybrid therapy (500 mg/8 h) com-
pared with other hybrid and concomitant regimens (500 mg/12 h),
which could affect one-to-one comparisons. A simpler dose schedule
could have achieved similar ER and better patient acceptance and
this deserves future study.
In summary, hybrid and concomitant NBQR show high ER
(≥90%) using a short 10 day regimen. Consequently, they should
be considered as first-line options in our area. In contrast, the OAC
regimen must no longer be recommended in this region.
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